The healthcare system of the U.S. is increasingly challenged by prescription drug shortages. But what are the root causes for this problem and how can these shortages be mitigated?
Which role plays effective supply chain management in that setting?
This paper addresses these questions and discusses possible approaches to strengthen the pharmaceutical supply chain in the U.S.
Table of Contents
1. Introduction
2. Impact of drug shortages
3. Causes of drug shortages
4. Actions for improvement
5. Recommendations to mitigate prescription drug shortages
5.1 Inventory management
5.2 Demand forecasting
5.3 Safety stocks
5.4 Manufacturing issues
5.4.1 Incentives for capacity expansions
5.4.2 Contingency plans
6. Conclusion
Objectives and Topics
This paper examines the increasing prevalence of prescription drug shortages within the U.S. healthcare system, identifies the root causes of these supply disruptions, and evaluates how effective supply chain management strategies can mitigate these risks to ensure patient safety and operational efficiency.
- Analysis of pharmaceutical supply chain complexity and stakeholder roles
- Evaluation of the economic and clinical impacts of medication scarcities
- Investigation of manufacturing and logistics-related triggers for shortages
- Review of current regulatory initiatives and industry-led interventions
- Development of strategic recommendations for inventory and demand management
Excerpt from the Book
Causes of drug shortages
The growing problem of drug shortages is determined by the interplay of various factors. On the one hand, it can be caused by natural disasters, epidemics or regulatory issues. But on the other hand, a large array of problems is caused by manufacturing and supply chain issues.
The pharmaceutical supply chain in the U.S. is very complex due to multiple independent actors (see Exhibit 1). Disruptions of the supply chain can therefore occur at various stages. The first actors in that chain are the suppliers of raw or bulk materials. Those deliver their goods to the pharmaceutical manufacturers, either brand-name or generic product manufacturers. At this stage, interruptions of the supply occur frequently as almost 80% of those raw materials come from outside the U.S. (Premier, 2012). Contamination problems, inadequate handling or just supply bottlenecks due to long lead times often lead to costly delays in manufacturing. These scarcities then ripple through the whole supply chain and can culminate in severe drug shortages.
The next key actors in the pharmaceutical supply chain are the drug manufacturers. In the last few years, a consolidation trend of the prescription drug manufacturers changed the industry. This involved foremost the market for generic, sterile injectable pharmaceuticals and as a result, this market is now largely represented by just seven manufacturers (Haninger et al., 2011). Additionally, IMS (2011) found that two-thirds of the products affected by shortages had only three or even fewer suppliers and most sterile injectables even have one manufacturer that produces at least 90% of it. As a consequence, as there are fewer sites producing a certain drug, interruptions in manufacturing can be even more damaging.
Summary of Chapters
Introduction: Provides an overview of the U.S. pharmaceutical market and highlights the alarming increase in drug shortages, particularly regarding generic injectables.
Impact of drug shortages: Discusses the negative consequences for patient care, including medication errors and increased financial burdens on hospitals and healthcare systems.
Causes of drug shortages: Explores the multifaceted factors contributing to supply disruptions, ranging from raw material sourcing issues to market consolidation among manufacturers.
Actions for improvement: Reviews recent attempts and governmental initiatives, such as the FDA notification obligation, to address and monitor the worsening situation.
Recommendations to mitigate prescription drug shortages: Offers specific strategies including enhanced inventory management, improved demand forecasting, better safety stocks, and addressing manufacturing-related incentives.
Conclusion: Summarizes the necessity of a holistic approach to supply chain management to reduce the frequency and severity of future drug shortages.
Keywords
Supply Chain Management, Prescription Drug Shortages, Pharmaceutical Industry, Inventory Management, Demand Forecasting, Sterile Injectables, Manufacturing Capacity, Generic Drugs, FDA, Patient Safety, Healthcare Logistics, Market Consolidation, Safety Stocks, Supply Disruptions.
Frequently Asked Questions
What is the core focus of this publication?
The paper focuses on the root causes and mitigation strategies for the increasing shortage of prescription drugs in the United States, specifically through the lens of supply chain management.
Which central topics are addressed?
Key topics include the complexity of the pharmaceutical supply chain, the impact of market consolidation, the role of manufacturers and wholesalers, and the importance of accurate demand forecasting.
What is the primary objective of this study?
The primary goal is to identify why supply disruptions occur and to provide actionable recommendations for healthcare stakeholders to strengthen the supply chain and reduce medication scarcities.
Which methodology is utilized?
The paper utilizes an analytical review of industry reports, supply chain management literature, and governmental regulatory frameworks to evaluate the current state and suggest improvements.
What is covered in the main body?
The main body examines the consequences of shortages, the systemic causes of these disruptions, current improvement efforts, and detailed recommendations for inventory and manufacturing strategies.
Which keywords characterize the work?
Key terms include Supply Chain Management, Drug Shortages, Inventory Management, Demand Forecasting, Pharmaceutical Industry, and Patient Safety.
How does market consolidation affect drug availability?
Consolidation has led to a reduced number of manufacturers, meaning that if one site faces a disruption, there are fewer alternative sources available, significantly increasing the likelihood and severity of shortages.
What role does the FDA play in mitigating these shortages?
The FDA acts as a regulatory body that has implemented reporting obligations, requiring manufacturers to notify the agency of production interruptions to allow for earlier intervention.
- Arbeit zitieren
- Isabelle Köhler (Autor:in), 2013, Drug Shortage Mitigation through Supply Chain Management, München, GRIN Verlag, https://www.grin.com/document/269511
